COPD-FORWARD: Once-Daily Triple Inhaler in Moderate-to-Severe COPD

Evaluating a single-inhaler triple therapy (ICS/LAMA/LABA) versus dual therapy for reducing exacerbations in adults with moderate-to-severe COPD.

Key eligibility criteria

• Adults 40–80 years
• Current or former smoker (≥ 10 pack-years)
• Post-bronchodilator FEV1 25–65%
• ≥ 1 exacerbation in past year

Additional criteria apply. A full eligibility review is completed by our coordinators during pre-screening — you may still qualify even if you're unsure about a criterion.